Enhancement of immunotoxin activity using chemical and biological reagents

British Journal of Cancer

Volumn 75, Issue 9, 1997, Pages 1347-1355

  Wu, M ^a  

^a UNIVERSITY OF LEEDS   (United Kingdom)

Author keywords

Ammonium chloride; Calcium channel antagonists; Cytotoxicity; Enhancement; Immunotoxins; Interferon; Monensin

Indexed keywords

AMMONIUM CHLORIDE; CALCIUM CHANNEL BLOCKING AGENT; CHLOROQUINE; CYCLOSPORIN A; DAUNORUBICIN; IMMUNOTOXIN; MONENSIN;

ARTICLE; CYTOTOXICITY; LYSOSOME; PRIORITY JOURNAL;

EID: 0030935838     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/bjc.1997.228     Document Type: Article

References (51)

1. Akiyama S, Gottesman MM, Hanover JA, FitzGerald D, Willingham MC and Pastan I (1984) Verapamil enhances the toxicity of conjugates of epidermal growth factor with pseudomonas exotoxin and antitransferrin receptor with pseudomonas exotoxin. J Cell Physiol 120: 271-279
2. Akiyama S, Seth P, Pirker R, FitzGerald D, Gottesman MM and Pastan I (1985) Potentiation of cytotoxic activity of immunotoxins on cultured human cells, Cancer Res 45: 1005-1007
3. Basham TY, Race ER, Campbell MJ, Reid TR, Levy R and Merigan TC (1988) Synergistic antitumor activity with IFN and monoclonal antiidiotype for murine B cell lymphoma: mechanism of action. J Immunol 141: 2855-2860
4. Cameron RB, McIntosh JK and Rosenberg SA (1988) Synergistic antitumor effects of combination immunotherapy with recombinant interleukin-2 and a recombinant hybrid α-interferon in the treatment of established murine hepatic metastases. Cancer Res 48: 5810-5817
5. Casellas P, Bourrie BJP, Gros P and Jansen FK (1984) Kinetics of cytotoxicity induced by immunotoxins, enhancement by lysosomotropic amines and carboxylic ionophores. J Biol Chem 259: 9359-9364
6. Casellas P, Ravel S, Bourrie BJP, Derocq JM, Jansen FK, Laurent G and Gros P (1988) T-lymphocyte killing by T101-ricin A chain immunotoxin: pH-dependent potentiation with lysosomotropic amines. Blood 72: 1197-1202
7. Chaudhary VK, Jinno Y, FitzGerald D and Pastan I (1990) Pseudomonas exotoxin contains a specific sequence at the carboxyl terminus that is required for cytotoxicity. Proc Natl Acad Sci USA 87: 308-312
8. Chignola R, Anselmi C, Serra MD, Franceschi A, Fracasso G, Pasti M, Chiesa E, Lord JM, Tridente G and Colombatti M (1995) Self-potentiation of ligand-toxin conjugates containing ricin A chain fused with viral structures. J Biol Chem 270: 23345-23351
9. Colombatti M, Dell'Arciprete L, Chignola R and Tridente G (1990) Carrier protein-monensin conjugates: enhancement of immunotoxin cytotoxicity and potential in tumor treatment. Cancer Res 50: 13385-13391
10. Curiel DT, Agarwal S, Wagner E and Cotten M (1991) Adenovirus enhancement of transferrin-polylysine-mediated gene delivery. Proc Natl Acad Sci USA 88: 8850-8854
11. Eidelman O, Schlegel R, Tralka T and Blumenthal R (1984) pH-dependent fusion induced by vesicular stomatitis virus glycoprotein reconstitutes into phospholipid vesicles. J Biol Chem 259: 4622-2628
12. Endo Y, Mitsui K, Motizuki M and Tsurugi K (1987) The mechanism of action of ricin and related toxic rectins on eukaryotic ribosomes. J Biol Chem 262: 5908-5912
13. FitzGerald D, Padmanabhan R, Pastan I and Willingham MC (1983) Adenovirus-induced release of epidermal growth factor and Pseudomonas toxin into the cytosol of KB cells during receptor-mediated endocytosis. Cell 32: 607-617
14. Florkiewicz R and Rose J (1984) A cell line expressing vesicular stomatitis virus glycoprotein fuses at low pH. Science 225: 721-723
15. Gottstein C, Winkler U, Bohlen H, Diehl V and Engen A (1994) Immunotoxins: is there a clinical value? Ann Oncol 5 (suppl. 1): s97-s103
16. Griffin T and Raso V (1991) Monersin in lipid emulsion for the potentiation of ricin-A chain immunotoxins. Cancer Res 51: 4316-4322
17. Griffin T, Rybak ME, Recht L, Singh M, Salimi A and Raso V (1993) Potentiation of antitumor immunotoxins by liposomal monensin. J Natl Cancer Inst 85: 292-298
18. Jaffrezou JP, Levade T, Kuhlein E, Thurneyssen O, Chiron M, Grandjeas H, Carriere D and Laurent G (1990) Enhancement of ricin A chain immunotoxin activity by perhexiline on established and fresh leukemia cells. Cancer Res 50: 5558-5566
19. Jaffrezou JP, Sikic BI and Laurent G (1994) Cyclosporine A and cyclosporine SDZ PSC 833 enhance anti-CD5 ricin A-chain immunotoxins in human leukemic T-cells. Blood 83: 482-489
20. Jansen FK, Jansen A, Dercoq JM, Carriere D, Carayon P, Veas F and Jaffrezou JP (1992) Golgi vacuolization and immunotoxin enhancement by monensin and perhexiline depend on a serum protein. Implications for intracellular trafficking. J Biol Chem 267: 12577-12682
21. Lendaro E, Ippoliti R, Belleli A, Brunori M, Evangelista V, Guidarini D and Benedetti PA (1994) Intracellular dynamics of ricin followed by fluorescence microscopy on living cells reveals a rapid accumulation of the dimeric toxin in the Golgi apparatus. FEBS Lett 344: 99-104
22. Marcil J, Ravindranath N and Sairam MR (1993) Cytotoxic activity of lutropin-gelonin conjugate in mouse leydig tumor-cells - potentiation of the hormonotoxin activity by different drugs. Mol Cell Endocrinol 92: 83-90
23. McIntosh DP, Edwards DC, Cumber AJ, Parnell GD, Dean CJ, Ross WCJ and Forrester JA (1983) Ricin B chain converts a non-cytotoxic antibody-ricin A chain conjugate into a potent and specific cytotoxic agent. FEBS Lett 164: 17-20
24. Mezei M and Nugeni FJ (1984) Method of encapsulating biologically active materials in multilamellar lipid vesicles. US Patent 4: 485054
25. Mollenhauer H, Morre DJ and Rowe LD (1990) Alteration of intracellular traffic by monensin, mechanism, specificity und relationship to toxicity. Biochimica et Biophysica Acta 1031: 225-246
26. O'Boyle KP, Colletti D, Mazurek C, Wang Y, Ray SK, Diamond B, Rosenblum MG, Epstein AL, Shochat D, Dutcher JP, Wiernik PH and Klein RS (1995) Potentiation of antiproliferative effects of monoclonal antibody LYM-1 and immunoconjugate LYM-1-gelonin on human Burkitts-lymphoma cells with Gamma-interferon and tumor-necrosis-factor. J Immunother 18: 221-230
27. Pai LH and Pastan I (1993) Immunotoxin therapy for cancer. JAMA 269: 78-81
28. Pearson JW, Hedrick E, Fogler WE, Bull RL, Ferris DK, Riggs CW, Wiltrout RH, Sivam G, Morgan AC, Groves ES and Longo DL (1990) Enhanced therapeutic efficacy against an ovarian tumor xenograft of immunotoxins used in conjunction with recombinant α-interferon. Cancer Res 50: 6379-6388
29. Pearson JW, Fogler WE, Volker K, Riggs CW, Gruys E, Groves ES, Wiltrout RH and Longo DL (1993) Restoration of interferon-alpha potentiation of a recombinant ricin-A chain immunotoxin following cytoreduction of xenografts of advanced ovarian-tumors. J Natl Cancer Inst 85: 907-912
30. Pirker R, FitzGerald DJP, Raschack M, Frank Z, Willingham MC and Pastan I (1989) Enhancement of the activity of immunotoxins by analogues of verapamil. Cancer Res 49: 4791-4795
31. Poole B and Ohkuma S (1981) Effect of weak bases on the intralysosomal pH in mouse peritoneal macrophages. J Cell Biol 90: 665-669
32. Roth JA, Ames RS, Fry K, Lee HM and Scannon PJ (1988) Mediation of reduction of spontaneous and experimental pulmonary metastases by ricin A chain immunotoxin 45-2D9-RTA with potentiation by systemic monensin in mice. Cancer Res 48: 3496-3501
33. Schlege R and Wade M (1985) Biologically active peptides of the vesicular stomititis virus glycoprotein. J Virol 53: 319-323
34. Seetharam S, Chaudhary VK, FitzGerald D and Pastan I (1991) Increased cytotoxic activity of pseudomonas exotoxin and two chimeric toxins ending in KDEL. J Biol Chem 266: 17376-17381
35. Siena S, Villa S, Bregni M, Bonnadonna G and Gianni AM (1987) Amantadine potentiates T lymphocyte killing by an anti-pan-T cell (CD4) ricin A-chain immunotoxin. Blood 69: 345-348
36. Singh M, Griffin T, Salimi A, Micetich RG and Atwal H (1994) Potentiation of ricin-A immunotoxin by monoclonal-antibody targeted monensin containing small unilamellar vesicles. Cancer Lett 84: 15-21
37. Smyth MJ, Pietersz GA and Mckenzie IFC (1987) Use of vasoactive agents to increase tumor perfusion and the antitumor efficacy of drug-monoclonal antibody conjugates. J Natl Cancer Inst 79: 1367-1373
38. Thrush GP, Lark LR, Clinchy BC and Vitetta ES (1996) Immunotoxins: an update. Annu Review Immunol 14: 49-71
39. Uhlin-hansen L and Yanagishita M (1995) Brefeldin A inhibits the endocytosis of plasma-membrane-associated heparan sulphate proteoglycans of cultured rat ovarian granulosa cells. Biochem J 310: 271-278
40. Vallera DA (1994) Immunotoxins: will their clinical promise be fulfilled? Blood 83: 309-317
41. Vitetta ES, Cushley W and Uhr JW (1983) Synergy of ricin A chain-containing immunotoxins and ricin B chain-containing immunotoxins in the in vitro killing of neoplastic human B cells. Proc Natl Acad Sci USA 80: 6332-6335
42. Vitetta ES, Fulton RJ and Uhr JW (1984) The cytotoxicity of cell-reactive immunotoxin containing ricin A chain is potentiated with an anti-immunotoxin containing ricin B chain. J Exp Med 160: 341-346
43. Wagner E, Curiel DT and Cotten M (1994) Delivery of drugs, proteins and genes into cells using transferrin as a ligand for receptor-mediated endocytosis. Adv Drug Delivery Review 14: 113-135
44. Wales R, Roberts LM and Lord JM (1993) Addition of an endoplasmic reticulum retrieval sequence to ricin A chain significantly increases its cytotoxicity to mammalian cells. J Biol Chem 268: 23986-23990
45. Wu M, Tang SL, Zang RJ and Yu H (1990) Selective killing of tumor cells by an immunotoxin composed of ricin and monoclonal antibody against Ia antigen. Int J Immunopharmacol 12: 235-239
46. Wu M, Miyazawa M and Nose M (1993) Immunotoxins as a new reagent for treatment of viral infection and autoimmune diseases. Drug Delivery System 8: 5-10
47. Wu M, Brown WL and Stockley PG (1995) Cell-specific delivery of bacteriophage-encapsidated ricin A chain. Bioconjugate Chem 6: 587-595
48. Wu YN, Gadina M, Taocheng JH and Youle RJ (1994) Retinoic acid disrupts the Golgi-apparatus and increases the cytosolic routing of specific protein toxins. J Cell Biol 125: 743-753
49. Yefenof E, Abboud G, Epszteyn S and Vitetta ES (1992) Treatment of premalignancy: prevention of lymphoma in radiation leukemia virus-inoculated mice by cyclosporin A and immunotoxin. Proc Natl Sci Acad USA 89: 728-732
50. Yokota S, Hara H, Guo Y and Seon BK (1990) Synergistic potentiation of in vivo antitumor activity of anti-human T-leukemia immunotoxins by recombinant α-interferon and daunorubicin. Cancer Res 50: 32-37
51. Yokota S, Okazaki M, Yoshida M and Seon BK (1993) Biodistribution and in vivo antitumor efficacy of the systemically administrated anti-tumor T-leukemia immunotoxins and potentiation of their efficacy by α-interferon. Leukemia Res 17: 69-79